What's the role of ibrutinib and venetoclax in CLL in light of data emerging from ASH 2022?  

Authored by @Neil E. Kay and @Yucai Wang The current FDA-approved, standard-of-care for frontline chronic lymphocytic leukemia (CLL) therapy includes continuous therapy with a Bruton tyrosine kinase inhibitor (BTKi) such as ibrutinib or acalabrutinib, with or without an anti-CD20 antibody, or o...